Ji-hea Kim

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K/Akt/mTOR and dipeptidylpeptidase Ⅳ (CD26).

CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K/Akt/mTOR and dipeptidylpeptidase Ⅳ (CD26).

Journal: Heliyon

Published: July 30, 2023

PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma.

PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma.

Journal: Biomedicines

Published: March 22, 2022

Generation of a human induced pluripotent stem cell line KUMi006 from a patient with multiple myeloma.

Generation of a human induced pluripotent stem cell line KUMi006 from a patient with multiple myeloma.

Journal: Stem cell research

Published: March 09, 2022

Generation of the human pluripotent stem cell lines KUMi005-A from a patients with multiple myeloma.

Generation of the human pluripotent stem cell lines KUMi005-A from a patients with multiple myeloma.

Journal: Stem cell research

Published: February 12, 2022

A human pluripotent stem cell line KUMi004-A generated from a patient with chronic lymphocytic leukemia.

A human pluripotent stem cell line KUMi004-A generated from a patient with chronic lymphocytic leukemia.

Journal: Stem cell research

Published: January 04, 2022

Generation of human induced iPSC KUMi003-A from acute promyelocytic leukemia (APL) M3.

Generation of human induced iPSC KUMi003-A from acute promyelocytic leukemia (APL) M3.

Journal: Stem cell research

Published: November 05, 2021

Generation of the induced pluripotent stem cell line KUMi001-A carrying the Philadelphia chromosome from a chronic myeloid leukemia patient.

Generation of the induced pluripotent stem cell line KUMi001-A carrying the Philadelphia chromosome from a chronic myeloid leukemia patient.

Journal: Stem cell research

Published: June 16, 2021

Generation of induced pluripotent stem cell line KUMi002-A with normal karyotype from a patient with Philadelphia chromosome-positive chronic myeloid leukemia.

Generation of induced pluripotent stem cell line KUMi002-A with normal karyotype from a patient with Philadelphia chromosome-positive chronic myeloid leukemia.

Journal: Stem cell research

Published: June 16, 2021

Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma.

Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma.

Journal: Frontiers in oncology

Published: February 22, 2021

CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells.

CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells.

Journal: Biochemical pharmacology

Published: January 31, 2021

Generation of normal induced pluripotent stem cell line KUMCi002-A from bone marrow CD34+ cells of patient with multiple myeloma disease having 13q deletion and IGH translocation.

Generation of normal induced pluripotent stem cell line KUMCi002-A from bone marrow CD34+ cells of patient with multiple myeloma disease having 13q deletion and IGH translocation.

Journal: Stem cell research

Published: September 15, 2020

Supporting data on enhanced reprogramming of human CD34+ hematopoietic stem cells to induced pluripotent stem cells using human placenta-derived cell conditioned medium.

Supporting data on enhanced reprogramming of human CD34+ hematopoietic stem cells to induced pluripotent stem cells using human placenta-derived cell conditioned medium.

Journal: Data in brief

Published: July 13, 2020

Showing 1-12 of 14

Last Updated: 09/26/2026